Abstract: Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.

Abstract: Oligosaccharides from bovine milk, whey and dairy products, and methods of producing bovine milk oligosaccharides are provided.

Abstract: The subject matter of the present disclosure generally relates to techniques for neuromodulation of a tissue that include applying energy (e.g., ultrasound energy) into the tissue to cause altered activity at a synapse between a neuron and a non-neuronal cell.

Abstract: The present invention relates to the use of contrast-enhanced ultrasound using microbubble-based ultrasound contrast agents to accomplish noninvasive subharmonic aided pressure estimation (SHAPE) in a region of interest (ROI) of a subject. The method of the invention provides a non-invasive, direct, and accurate method for pressure estimation.

Abstract: Methods of reducing milk glycans, and thus enteric pathogens that use such glycans as carbon sources, in the gut of nursing mammals.

Abstract: A method for manufacturing a bioactive implant including the steps of (a) forming a mixture of an bioactive agent and a setting agent capable of transitioning from a flowable state to a rigid state; (b) converting the mixture into a flowable state; and (c) transitioning the mixture into a solid state in a shape of the implant.

Abstract: Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.

Abstract: Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.

Abstract: Oligosaccharides from bovine milk, whey and dairy products, and methods of producing bovine milk oligosaccharides are provided.

Abstract: Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.

Abstract: A method for manufacturing a bioactive implant including the steps of (a) forming a mixture of an bioactive agent and a setting agent capable of transitioning from a flowable state to a rigid state; (b) converting the mixture into a flowable state; and (c) transitioning the mixture into a solid state in a shape of the implant.

Abstract: An implement system for a machine. The implement system includes a boom, an implement, a roller assembly and a carriage. The boom has a telescopic structure and a first end. The implement is coupled to the first end of the boom. The roller assembly is configured to be coupled to the machine. The carriage is engaged with the roller assembly and is coupled to the boom. The carriage is configured to move linearly along a longitudinal axis of the machine between a first position and a second position.

Abstract: The pntAB locus may provide for increased alcohol tolerance in a microorganism, through expression of one or both of the pntA and pntB genes. A microorganism may have increased alcohol tolerance due to a transformation of the microorganism or an ancestor of the microorganism utilizing one or both of the pntA and pntB genes. The microorganism may be, for example, of a bacterial or fungal species. According to some exemplary embodiments, the microorganism may be a lactic acid bacterium.

Abstract: A method and apparatus for automated projection mapping previsualization is provided. A computer model of an object is received, at a controller of a device, from a publicly accessible remote mapping server, the computer model comprising a publicly available three-dimensional computer model, the computer model defining an object in geographic coordinates and elevation coordinates, the object located at given geographic coordinates. The controller generates a time dependent previsualization projection mapping model for the object using images to be projected onto the object, the computer model, and data for generating one or more of Sun behavior and the Moon behavior at the given geographic coordinates. The controller controls a display device to render a previsualization of the time dependent previsualization projection mapping model.

Abstract: Methods of reducing milk glycans, and thus enteric pathogens that use such glycans as carbon sources, in the gut of nursing mammals.

Abstract: Oligosaccharides from bovine milk, whey and dairy products, and methods of producing bovine milk oligosaccharides are provided.

Abstract: A bioreactor control system comprises a batch server for controlling a bioreactor system in response to a recipe, a batch software system for generating a control sequence for the bioreactor system via the batch server for implementing the recipe, and a recipe conversion system that inputs the recipe into the batch software system. Preferably, the recipe conversion system reads a word processor file containing the recipe and interprets styles applied to text in the word processor file as indicating equipment and phases of the recipe to the recipe conversion system. Generally, the bioreactor system includes one or more bioreactors and additional hardware to perform the upstream and downstream processing. The document properties of the word processor file containing the recipe are applied as header information for the recipe input into the batch software system.

Abstract: Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.

Abstract: The pntAB locus may provide for increased alcohol tolerance in a microorganism, through expression of one or both of the pntA and pntB genes. A microorganism may have increased alcohol tolerance due to a transformation of the microorganism or an ancestor of the microorganism utilizing one or both of the pntA and pntB genes. The microorganism may be, for example, of a bacterial or fungal species. According to some exemplary embodiments, the microorganism may be a lactic acid bacterium.

Abstract: The technology described herein relates to methods of inducing cell death. The technology described herein further relates to treating conditions including cancers and autoimmune diseases comprising administering inhibitors of double strand break repair. Also described herein are inhibitors of double strand break repair and methods of screening for such inhibitors.